Compare Mercadolibre Inc (MELI) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mercadolibre Inc vs Sana Biotechnology Inc — how do they compare? Mercadolibre Inc trades at $1,889.85 (market cap $94.13B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: Mercadolibre Inc is far larger — about 112.5× Sana Biotechnology Inc's market cap, and Mercadolibre Inc is trading nearer its 52-week high, Sana Biotechnology Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mercadolibre Inc for 117 Days and Sana Biotechnology Inc for 23 Days on average.
| MELI | SANA | |
|---|---|---|
Market Cap | $94.13B | $836.71M |
Volume | 273,781 | 4,507,444 |
Sector | Consumer Cyclical | Health |
52-Week High | $2.36K | $5.92 |
52-Week Low | $1.55K | $2.68 |
Typical Hold Time | 117 Days | 23 Days |
Enterprise Value | $101.77B | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MercadoLibre (MELI) trades at $1,856.66, down 0.86% on the day, with a bullish technical signal supported by moving averages. The company reported strong revenue growth to $28.89 billion in 2025, though net income margins dipped to 6.91%. Recent news highlights expansion in Brazil, including one-hour delivery and pharmacy business growth, while its fintech credit portfolio surged 75% in Q2 2026 to $16.4 billion.
Outlook remains positive with analyst consensus at 'Buy' and a $2,170 price target, but risks include profit margin pressure and macroeconomic headwinds in Latin America. The stock's high P/E of 50.51 suggests growth expectations are priced in, requiring sustained execution to justify valuation.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent news highlights multiple investor conference presentations and ongoing legal scrutiny regarding fiduciary duties.
Despite strong analyst support (82% buy ratings), SANA's lack of revenue generation and negative profitability metrics present substantial investment risk. The company's cash flow remains negative, requiring continued financing. Near-term catalysts include upcoming Q3 earnings and clinical developments, but investors should weigh the high-risk profile against potential long-term biotechnology breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mercadolibre Inc
MercadoLibre runs the largest e-commerce marketplace in Latin America, connecting a network of more than 140 million active users and 1 million active sellers as of the end of 2021 across an 18-country footprint. The company also operates a host of complementary businesses, with shipping solutions (Mercado Envios), a payment and financing operation (Mercado Pago), advertisements (Mercado Clics), classifieds, and a turnkey e-commerce solution (Mercado Shops) rounding out its arsenal. MercadoLibre generates revenue from final value fees, advertising royalties, payment processing, insertion fees, subscription fees, and interest income from consumer and small-business lending.
Read more on MELI →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
